Skip to Main Content
Table 4.

OR and 95% CI values of total prostate cancer stratified by aspirin use since age 20 years in 691 matched pairs nested in the Health Professionals Follow-up Study, 1993 to 2000

T. vaginalis antibody seronegative
T. vaginalis antibody seropositive
Cases/controlsOR (95% CI)Cases/controlsOR (95% CI)*Multivariable-adjusted OR (95% CI)*,
Aspirin use since age 20 y      
    Infrequent use (0-19% of the time) 154/148 1.00 32/15 2.00 (1.02-3.89) 2.05 (1.05-4.02) 
    Moderate use (20-79% of the time) 181/201 1.00 23/19 1.33 (0.70-2.55) 1.37 (0.71-2.62) 
    Regular use (80-100% of the time) 241/243 1.00 29/27 1.03 (0.59-1.80) 1.05 (0.60-1.85)§ 
T. vaginalis antibody seronegative
T. vaginalis antibody seropositive
Cases/controlsOR (95% CI)Cases/controlsOR (95% CI)*Multivariable-adjusted OR (95% CI)*,
Aspirin use since age 20 y      
    Infrequent use (0-19% of the time) 154/148 1.00 32/15 2.00 (1.02-3.89) 2.05 (1.05-4.02) 
    Moderate use (20-79% of the time) 181/201 1.00 23/19 1.33 (0.70-2.55) 1.37 (0.71-2.62) 
    Regular use (80-100% of the time) 241/243 1.00 29/27 1.03 (0.59-1.80) 1.05 (0.60-1.85)§ 
*

Estimated by unconditional logistic regression, including terms for T. vaginalis antibody serostatus, age, time of day, season and year of blood draw, and PSA screening history before blood draw.

Adjusted for race (Caucasian, non-Caucasian) and cumulative family history of prostate cancer through 1996.

Percentage of years that aspirin was used with any frequency.

§

P values for interaction with aspirin use = 0.11.

Close Modal

or Create an Account

Close Modal
Close Modal